Publications by authors named "Jean Lecot"

Claim this Profile
F
First-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending doses clinical study to assess the safety, tolerability, and pharmacokinetics of cipargamin administered intravenously in healthy adults.
Vinay Kumar Venishetty, Jean Lecot, Amanda Nguyen, Jie Zhang, William T Prince

Antimicrob Agents Chemother· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concentration-QTcF Modeling of Icenticaftor from a Randomized, Placebo- and Positive-Controlled Thorough QT Study in Healthy Participants.
Ganesh R Iyer, Borje Darpo, Hongqi Xue, Jean Lecot, Julia Zack

Clin Pharmacol Drug Dev· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of triclabendazole and its metabolite exposure on the heart-rate-corrected QT intervals: A randomized, placebo- and positive-controlled thorough QT study in healthy individuals.
William T Prince, Vinay Kumar Venishetty, Jean Lecot, Kasra Shakeri-Nejad, Cathy Gray

Clin Transl Sci· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma.
Gail M Gauvreau, Jens M Hohlfeld, J Mark FitzGerald, Louis-Philippe Boulet, Donald W Cockcroft, Jean R Lecot

Eur Respir J· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.
Nicolino Ruperto, Pierre Quartier, Nico Wulffraat, Patricia Woo, Angelo Ravelli, Jean Lecot

Arthritis Rheum· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis